merck post solid result led rapid keytruda gain
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
merck combin wide line-up high-margin drug
pipelin new drug ensur strong return invest
capit long term merck worst
patent cliff remov heighten gener
competit compani experienc past five year
sever year moder research develop
product merck drug develop strategi yield
merck new product mitig gener competit
offset recent major patent loss particular keytruda
cancer repres key blockbust multi-billion-dollar
potenti hold first-mov advantag one largest
cancer indic non-small-cel lung cancer also expect
new cancer drug combin propel merck overal
drug sale howev expect intens competit cancer
market sever competit drug like report import
clinic data headwind includ
gener competit notabl cardiovascular drug zetia
vytorin like creat major drag overal growth
migrain safeti question end
sever year mix result merck product
improv compani shift toward area unmet
medic need owe side effect lack compel efficaci
merck experienc major setback cardiovascular diseas
drug anacetrapib tredapt rolofyllin tra along
develop osteoporosi drug odanacatib despit
setback merck solid success includ solid launch
drug keytruda oncolog follow success
merck shift focu toward area unmet medic need
specialty-car area keytruda lead new direct
expect keytruda leadership non-smal cell lung cancer
key driver growth firm next sever year
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
merck make pharmaceut product treat sever condit
number therapeut area includ cardiovascular diseas asthma
cancer infect within cancer firm immuno oncolog platform
grow major contributor overal sale compani also
substanti vaccin busi treatment prevent hepat
pediatr diseas well hpv shingl geograph
perspect close half compani sale gener unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fair valu estim base
merck post solid result led rapid keytruda
buoy robust keytruda sale merck report solid third-
quarter result slightli ahead consensu
expect expect signific chang
minor
out-performance continu view merck fairli valu
upsid compani strong immuno-oncolog
platform larg stock howev continu view
strength platform led keytruda major
reflect strong innov occur merck
support wide moat outsid oncolog merck
innov early-stag drug improv virolog
hiv drug phase ii data vaccin
pneumococc vaccin phase ii infant data
quarter keytruda growth year-over-year
help off-set gener competit older drug lead
overal growth similar top-lin growth rate
expect continu next three year keytruda
gain strong market share sever cancer type
includ largest indic first-lin non-smal cell
lung cancer nsclc track post close
billion sale expect peak sale drug
billion base continu market penetr
nsclc well smaller cancer indic includ
skin bladder renal head neck cancer keytruda
lead efficaci first-lin nsclc support gain
almost immuno-oncolog market
outsid keytruda merck remain drug continu
perform expect except human
papillomaviru vaccin gardasil post extra gain
partli due stockpil compani second largest drug
januvia/janumet expect minor
declin continu base weak price power
diabet market also gener pressur continu weigh
cardiovascular drug zetia vytorin well
deeper dive outlook keytruda
competit immuno oncolog drug pleas see report
bristol-my pleas note merck stock price
increas sinc report publish view
merck fairli valu
outsid result merck also announc rais
dividend new billion share repurchas
program believ strong cash flow gener
firm easili support use cash
increas fair valu estim
per share base strong clinic data cancer drug
keytruda support increas use drug keytruda
key merck valuat expect leader
immuno-oncolog market expect drug reach
peak sale billion larg base strong
efficaci sever cancer type includ lung head
neck melanoma sever cancer indic
look entir compani next decad
expect merck post annual top-lin growth
new drug offset drug lost gener competit
potenti game changer growth rate includ
compani pipelin immuno-oncolog drug move
quickli clinic develop merck still face
gener competit nasonex zetia vytorin
next year howev believ pipelin drug
growth exist drug off-set near-term gener
headwind overal expect larg stabl margin
near term minor improv
specialty-ori drug launch carri strong price
power need less market support
larg base low volatil cash flow
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
flow support power salesforc sell
current market drug also serv deterr
develop drug compani seek launch compet
opportun extern develop drug cash flow
also put compani rare posit support
approxim million need averag
bring new drug market power
merck research laboratori still hold
vast databas knowledg help compani
maintain leadership posit drug discoveri
develop also compani entrench
immuno-oncolog area strengthen
merck competit posit drug carri
vaccin add layer competit protect
intellectu properti cost advantag merck
face deterior moat trend past merck
competit advantag stabil patent protect
still shield major drug competit
compani develop enough new drug off-set
eventu patent loss pipelin side merck made
strateg shift acceler move focu
unmet medic need specialti care area
debilit lethal diseas strateg shift help
increas product fight back
follow three neg trend first post-vioxx era
fda grown
primary-car diseas tend approv safe
drug drug highli need area cancer
insur compani steadili reduc
coverag follow-on drug forc drug firm push
true innov reduc power distribut
network lastli govern develop market
increasingli use compar effect program
aggress push price negoti
divers inelast product portfolio rate merck
uncertainti low scenario analysi assum
base-cas fair valu estim bull case
probabl bear case probabl
project fair valu estim rel base case
scenario analysi show minor varianc henc low
key factor affect scenario analysi includ
degre success brand drug pipelin along
magnitud market pressur current market
drug within pipelin import driver
valuat keytruda cancer addit unknown
full impact biosimilar competit remicad
immunolog diseas weigh certainti
patent economi scale power intellectu
base buoy merck busi keep well shield
competit bedrock merck wide moat
patent protect continu keep competitor
bay compani strive introduc next
gener drug compani enorm cash
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
respons challeng merck strateg focu
toward unmet medic need increas probabl
success regulatori agenc support stronger
price power payer altern exist
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
okeytruda look best posit immuno-
advantag import indic first-lin non-
landscap buoy
omerck key drug januvia look potenti safer
diabet drug follow-on combin
drug drive futur growth
oth launch biosimilar competit immunolog
drug remicad continu caus drag
owhil major patent loss behind
compani sever major product face gener
competit next coupl year includ
zetia vytorin
omerck support strong dividend yield look
secur base wide diversifi portfolio drug
omerck lack intern combin drug
keytruda could limit potenti keytruda
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
merck remain solid financi foot compani
close debt/capit strong cash flow
expect next sever year
strengthen balanc sheet howev merck signal
strong willing make acquisit histor
firm tend make sever bolt-on acquisit
year given merck made major
acquisit sinc schere plough deal
expect make larger acquisit near term
beyond acquisit expect steadi futur dividend
support pay-out ratio close rel
merck near-term risk larg center market accept
new drug like pharmaceut compani merck
face regulatori risk fda product delay
nonapprov could hurt stock also grow power
manag care price-sensit
addit merck face remain legal risk
vioxx major plaintiff particip
billion settlement holdout could ring major
addit settlement also litig risk remain
patient took one-tim blockbust fosamax
osteoporosi medicin link infrequ
seriou side effect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mr kenneth frazier ceo/chairman board/
repres date owner name posit common share held report holder issuer
va collegeamerica inc fd amer
share
fund
share
fund
ken frazier took ceo dick clark begin
appoint chairman board late
clark near retir age view
new leader continu merck past strategi
red flag shift leadership approach frazier
part success strategi guid clark frazier
almost two decad experi merck across
major divis posit well lead
compani also deserv much credit
success handl vioxx litig held
merck gener counsel posit major
litig merck board pack current retir
ceo lead quid pro quo compens
top execut
rate compani stewardship standard merck
shown reason use capit purchas
schering-plough fair price brought sever
import pipelin product includ keytruda
allow cost-cut opportun hand
billion acquisit cubist seem like stretch
make valuat work especi announc
sooner-than-expect patent loss key drug cubicin
merck heavi fund past decad
produc mix result sever import new drug
also mani failur howev compani final
shift focu toward area specialti care away
primari care lead improv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pharma moat outlook compani still strong
analysi pharma compani continu
see industri well posit strong econom
moat analysi reaffirm moat
rate increas bayer moat wide
narrow bayer divestitur materi scienc group
combin strong drug busi well-posit
bolster monsanto
acquisit led us upgrad moat rate wide
moat pharma compani
increas focu innov area unmet medic
need enabl strong price power off-set increas
negoti power pharmaci benefit manag
 restrict price develop market outsid
 drug carri patent protect allow firm
charg near monopolist price drug true price
power determin sever factor includ benefit
patient uniqu govern outsid
 pbm within increasingli push
back drug price medicin lack signific
benefit overal stronger drug uniqu
efficaci stronger drug price power result
major drug compani focus
develop effort area signific unmet medic
addit segment within pharma firm anim
health consum healthcar carri strong moat
augment moat strength deriv human brand
drug segment overal moat analysi guid
under-valued call bayer glaxosmithklin
valuat
complet overview pharma moat analysi
pleas see report pharma moat outlook compani
still strong posit analyz key point
around moat larg pharmaceut industri
support keytruda merck post solid outlook
immuno oncolog appear underappreci jul
merck report second-quart result slightli ahead
consensu expect expect
chang fair valu estim base minor
out-performance continu view compani
under-valued larg due bullish expect
cancer drug keytruda almost billion sale
project ahead consensu expect
billion also merck lead posit immuno-oncolog
led keytruda help reinforc wide moat rate
firm
quarter strong keytruda growth
lead total sale growth growth rate
larg continu remaind year
gener pressur heavi brand hepat
competit remain back half year
headwind reced new indic
keytruda continu drive strong growth
drug next sever year particular expect
approv keytruda first-lin squamou non-small-
cell lung cancer oct food drug
administr deadlin european approv use
keytruda combin chemotherapi nsclc
patient regardless express end
year lung cancer expect merck gain
late-stag diseas market cede share roch
bristol smaller biomark diseas area show
express alk/egfr tmb expect
keytruda gain new indic liver cancer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
outsid immuno-oncolog major merck
product matur face poor growth prospect
except anesthesia-rel drug bridon hpv
vaccin gardasil intern market anim
healthcar divis show strong growth
quarter continu post steadi gain
next sever year
deeper dive outlook keytruda
competit immuno oncolog drug pleas see report
bristol-my
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
